Lee Blackburn

Lee Blackburn

Auto-generated profile, based on publicly available information

Lee Blackburn

Department of Anaesthesiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2014 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
LBLee Blackburn
Lee Blackburn
KOKaye Ottaway
Kaye Ottaway
BABrian J Anderson
Brian J Anderson

14 March 2014 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
LBLee Blackburn
Lee Blackburn
KOKaye Ottaway
Kaye Ottaway
BABrian J. Anderson
Brian J. Anderson

28 January 2014 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
LBLee Blackburn
Lee Blackburn
NANicole Almenrader
Nicole Almenrader
PLPeter Larsson
Peter Larsson
BABrian J. Anderson
Brian J. Anderson

30 May 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
COConor O'Hanlon
Conor O'Hanlon
NHNick Holford
Nick Holford
BABrian J. Anderson
Brian J. Anderson
MGMark Greaves
Mark Greaves
LBLee Blackburn
Lee Blackburn
JHJacqueline A. Hannam
Jacqueline A. Hannam
Cardiopulmonary bypass (CPB) can alter pharmacokinetic (PK) parameters and the drug may adsorb to the CPB device, altering exposure. Cefazolin is a beta‐lactam antibiotic used for antimicrobial prophylaxis during cardiac surgery supported by CPB. Adsorption of cefazolin could result in therapeutic failure. An ex vivo study was undertaken using CPB devices primed and then dosed with cefazolin and samples were obtained over 1 hour of recirculation. Twelve experimental runs were conducted using different CPB device sizes (neonate, infant, child, and adult), device coatings (Xcoating™, Rheoparin®, PH.I.S.I.O), and priming solutions. The time course of saturable binding, using Bmax (binding capacity), Kd (dissociation constant), and T2off (half‐time of dissociation), described cefazolin adsorption. Bmax estimates for the device sizes were neonate 40.0 mg (95% CI 24.3, 67.4), infant 48.6 mg (95% CI 5.97, 80.2), child 77.8 mg (95% CI 54.9, 103), and adult 196 mg (95% CI 191, 199). The Xcoating™ Kd estimate was 139 mg/L (95% CI 27.0, 283) and the T2off estimate was 98.4 min (95% CI 66.8, 129). The Rheoparin® and PH.I.S.I.O coatings had similar binding parameters with Kd and T2off estimates of 0.169 mg/L (95% CI 0.01, 1.99) and 4.94 min (95% CI 0.17, 59.4). The Bmax was small (< 10%) relative to a typical total patient dose during cardiac surgery supported by CPB. A dose adjustment for cefazolin based solely on drug adsorption is not required. This framework could be extended to other PK studies involving CPB.